Effect of Trikafta on bone density, body composition and exercise capacity in CF: A pilot study

Area of Science:

• Medical Research
• Pulmonology
• Metabolic Studies

Background:

• Cystic Fibrosis (CF) pulmonary disease management is advanced by Trikafta.
• Limited data exists on Trikafta's impact on bone mineral density (BMD), body composition, and exercise capacity.

Purpose of the Study:

• To evaluate the effects of Trikafta on BMD, body composition, and exercise capacity in CF patients.
• To compare these effects against a control group not receiving Trikafta.

Main Methods:

• Pilot single-center study involving nine CF patients initiating Trikafta and nine controls.
• Measurements included BMD, body composition, spirometry, lung clearance index (LCI), sweat tests, 6-minute walk test (6MWT), and cardio-pulmonary exercise test (CPET).
• Data collected three months post-Trikafta initiation and compared to baseline or previous measurements.

Main Results:

• Significant increases in BMI, hip BMD, and spine BMD observed in the study group.
• Improvements in lean body mass, fat mass z-scores, and 6MWT distance.
• As expected, FEV1%pred increased and sweat chloride decreased; improved ventilatory efficiency noted in CPET.

Conclusions:

• This is the first study to evaluate the metabolic effects of Trikafta.
• Results are encouraging, indicating potential benefits beyond pulmonary disease.
• Larger, long-term studies are needed to elucidate underlying physiological mechanisms.